drugset / Trial / NCT05172999

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

NCT05172999

Phase 2/3 Completed 30 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.

Timeline

Start
2022-01-08
Primary completion
2025-12-30
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Loxenatide Unknown 0.1 mg
Subject Loxenatide Unknown 0.2 mg